{"id":"fusidic-acid-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fusidic acid is a steroid antibiotic that targets bacterial elongation factor G (EF-G), a critical component of the bacterial ribosome. By binding to EF-G and blocking its function, it prevents the translocation of peptides during protein synthesis, effectively halting bacterial growth. It is bacteriostatic and has particular activity against Gram-positive bacteria, including Staphylococcus aureus.","oneSentence":"Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G and preventing peptide chain elongation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:38.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial skin and soft tissue infections"},{"name":"Staphylococcus aureus infections (topical)"}]},"trialDetails":[{"nctId":"NCT06911424","phase":"PHASE3","title":"Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis","status":"RECRUITING","sponsor":"Baxis Pharmaceuticals, Inc.","startDate":"2025-03-21","conditions":"Bacterial Conjunctivitis","enrollment":400},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""},{"nctId":"NCT03395132","phase":"PHASE3","title":"Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2018-07-31","conditions":"Infected Atopic Dermatitis/Eczema","enrollment":68},{"nctId":"NCT06839638","phase":"NA","title":"Efficacy of 100% Trichloroacetic Acid Vs. Cryotherapy in Xanthelasma Palpebrarum","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nishtar Medical University","startDate":"2024-09-07","conditions":"Xanthelasma Palpebrarum","enrollment":60},{"nctId":"NCT03849989","phase":"NA","title":"M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2018-12-21","conditions":"Hailey Hailey Disease","enrollment":11},{"nctId":"NCT03816618","phase":"EARLY_PHASE1","title":"The Healing Effects Of Honey and Hydrogel Products On The Diabetic Foot","status":"COMPLETED","sponsor":"Cyberjaya University College of Medical Sciences","startDate":"2020-01-01","conditions":"Diabetic Foot","enrollment":120},{"nctId":"NCT03173053","phase":"NA","title":"S. Aureus Decolonization in HPN Patients.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-02-08","conditions":"Staphylococcus Aureus, Motility Disorder","enrollment":63},{"nctId":"NCT03378427","phase":"NA","title":"Tedizolid Prolonged Treatment for Prosthetic Joint Infections","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2018-08-28","conditions":"Prosthetic Joint Infection","enrollment":35},{"nctId":"NCT02570490","phase":"PHASE3","title":"Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2015-11","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":716},{"nctId":"NCT00948142","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2009-08","conditions":"Skin Diseases, Bacterial","enrollment":198},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT03105505","phase":"PHASE4","title":"The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis","status":"UNKNOWN","sponsor":"Barzilai Medical Center","startDate":"2017-04-28","conditions":"Inflammation of the Eyelids","enrollment":75},{"nctId":"NCT00133874","phase":"PHASE3","title":"Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Skin Infections, Bacterial","enrollment":520},{"nctId":"NCT00718315","phase":"PHASE3","title":"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Non-Small Cell Lung Cancer","enrollment":201},{"nctId":"NCT02123628","phase":"PHASE4","title":"Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2007-06","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT01113125","phase":"PHASE3","title":"Scars After Central Venous Catheters","status":"UNKNOWN","sponsor":"Mette Møller Handrup","startDate":"2010-03","conditions":"Hypertrophic Scars, Keloids","enrollment":60},{"nctId":"NCT01153828","phase":"","title":"EU PV for Retapamulin-Prescribing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11","conditions":"Impetigo","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fusidic Acid 1%","genericName":"Fusidic Acid 1%","companyName":"Baxis Pharmaceuticals, Inc.","companyId":"baxis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G and preventing peptide chain elongation. Used for Bacterial skin and soft tissue infections, Staphylococcus aureus infections (topical).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}